# ARS Pharmaceuticals, Inc. (SPRY)

> Source: Nexqual · https://nexqual.com/SPRY · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, ARS Pharmaceuticals, Inc. (SPRY), nexqual.com/SPRY" · informational, not investment advice.

**Price:** USD 4.07 (+3.56% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 4.07 · day 3.94–4.1 · 52w 3.89–13.15 · market cap null · NGM

## Key facts
- 1 of 80 tracked superinvestors hold SPRY (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 22.5 (range 15–30).
- Total return with dividends: 1Y -59.7% vs S&P 500 +18.1%; 5Y -58.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-10, EPS estimate USD -0.33, revenue estimate $42.0M.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold SPRY. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Daniel Loeb | Third Point | 0.17% | $8.0M | Unchanged |

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 22.5 (low 15, high 30).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | Leerink Partners | Target lowered | Outperform | $24 → $18 |
| 2026-06-25 | Leerink Partners | Target lowered | Outperform | $25 → $24 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -59.7% | -58.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -59.9% | -16.2% |
| Volatility (annualized) | 74.7% | 68.4% |
| Max drawdown | -69.9% (Jan 2026→Oct 2026) | -77.6% (Jun 2025→Sep 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/SPRY · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt